Effect of Acid Pump Antagonist (Revaprazan, Revanex(R)) on Result of 13C Urea Breath Test in Patients with Helicobacter pylori Associated Peptic Ulcer Disease.
- Author:
Ju Hyun OAK
1
;
Woo Chul CHUNG
;
Sung Hoon JUNG
;
Kang Hyun CHOI
;
Eun Jung KIM
;
Bong Koo KANG
;
Borami KANG
;
Si Eun KONG
;
Chang Nyol PAIK
;
Kang Moon LEE
Author Information
- Publication Type:Original Article ; English Abstract
- Keywords: Acid pump antagonist; Helicobacter pylori; Urea breath test
- MeSH: *Breath Tests; Carbon Isotopes; False Negative Reactions; Female; Helicobacter Infections/complications/*diagnosis; *Helicobacter pylori; Humans; Male; Middle Aged; Peptic Ulcer/*drug therapy/microbiology; Proton Pump Inhibitors/*therapeutic use; Pyrimidinones/*therapeutic use; Tetrahydroisoquinolines/*therapeutic use; Urea/*diagnostic use
- From:The Korean Journal of Gastroenterology 2011;57(1):8-13
- CountryRepublic of Korea
- Language:Korean
- Abstract: BACKGROUND/AIMS: Revaprazan (Revanex(R)) is a novel proton pump inhibitor (PPI) that has a somewhat different effect on proton pump compared with the other PPI's, also (called as 'acid pump antagonist'). We aimed to examine the false negative rate of 13C-urea breath test (UBT) in the patients with Helicobacter pylori (H. pylori) associated peptic ulcer disease who were treated with revaprazan and evaluate the anti-urease activity of revaprazan. METHODS: Total 55 patients were enrolled in this study. They received EGD examination between January 2009 and December 2009 and diagnosed histologically as H. pylori associated peptic ulcer disease. All patients took revaprazan only. Three patients were excluded because of underlying chronic disease and inappropriate breath sampling. The remaining 52 patients had UBT at 0, 2 and 4 weeks of revaprazan use. After 2 weeks of the cessation of revaprazan, they had the fourth UBT. RESULTS: At 2 and 4 weeks, the false negative rates of UBT were 5.8% and 23.1%, respectively (p=0.05). After 2 weeks of the cessation, the cases of the false negative result were five. Four out of five patients had prolonged negative results on two or three successive tests, and baseline 13C difference value did not predict the false negative results. CONCLUSIONS: False negative results of UBT were common and increased with prolonged use of acid pump antagonist. As PPI, it had also anti-urease activity and most patients (47/52, 90.4%) reverted to positive results by 2 weeks after the cessation of taking the medication.
